Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H11NO3 |
| Molecular Weight | 145.1564 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)CCC(=O)CN
InChI
InChIKey=YUUAYBAIHCDHHD-UHFFFAOYSA-N
InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3
| Molecular Formula | C6H11NO3 |
| Molecular Weight | 145.1564 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00992Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021415s004lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00992
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021415s004lbl.pdf
Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy. Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Methyl aminolevulinate is used for topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map00860 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | METVIXIA Approved UseMETVIXIA Cream in combination with Aktilite CL128 lamp red light illumination is indicated for treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratoses of the face and scalp in immunocompetent patients. This photodynamic therapy should be used in conjunction with appropriate lesion preparation in the physician’s office when other therapies are considered medically less appropriate. Launch Date2004 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 g single, topical Dose: 1 g Route: topical Route: single Dose: 1 g Sources: |
unhealthy, adult n = 383 Health Status: unhealthy Condition: actinic keratosis Age Group: adult Population Size: 383 Sources: |
Disc. AE: Pain localised... AEs leading to discontinuation/dose reduction: Pain localised (1%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Pain localised | 1% Disc. AE |
1 g single, topical Dose: 1 g Route: topical Route: single Dose: 1 g Sources: |
unhealthy, adult n = 383 Health Status: unhealthy Condition: actinic keratosis Age Group: adult Population Size: 383 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. | 2004 |
|
| [Eliminating light-induced skin cancer without operation]. | 2004 |
|
| Photodynamic therapy for subungual Bowen's disease. | 2004 Aug |
|
| [Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): practical experiences in problem-patients with actinic keratoses and basal cell carcinomas]. | 2004 Dec |
|
| A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. | 2004 Jul |
|
| Gateways to clinical trials. | 2004 Jul-Aug |
|
| Transdermal delivery from a lipid sponge phase--iontophoretic and passive transport in vitro of 5-aminolevulinic acid and its methyl ester. | 2004 Nov 24 |
|
| A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. | 2005 |
|
| Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. | 2005 Apr |
|
| Methyl aminolaevulinate photodynamic therapy for Bowen's disease: a practical option? | 2005 Feb |
|
| Methyl aminolaevulinate photodynamic therapy in practice: treatment protocol. | 2005 Feb |
|
| Practical aspects of methyl aminolaevulinate photodynamic therapy. | 2005 Feb |
|
| Topical photodynamic therapy for Bowen's disease. | 2005 Feb |
|
| Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. | 2005 Feb |
|
| Pain, pain relief and other practical issues in photodynamic therapy. | 2005 Feb |
|
| Photodynamic therapy. | 2005 Feb |
|
| Gateways to clinical trials. | 2005 Jul-Aug |
|
| Gateways to clinical trials. | 2005 Jun |
|
| [Reader's letter concerning K. Kreutzer, B.Bonnekoh, I. Franke, H. Gollnick. Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (Photdyn 501): practical experiences in problem patients with actinic keratoses and basal cell carcinomas. JDDG 2004,12:992-999]. | 2005 May |
|
| Gateways to clinical trials. | 2005 May |
|
| Influence of light exposure on the kinetics of protoporphyrin IX formation in normal skin of hairless mice after application of 5-aminolevulinic acid methyl ester. | 2005 Nov |
|
| Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas. | 2005 Sep-Oct |
|
| Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. | 2006 |
|
| Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. | 2006 |
|
| Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. | 2006 Apr |
|
| Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. | 2006 Apr |
|
| Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice. | 2006 Apr |
|
| The effect of folic acid on porphyrin synthesis in tumors and normal skin of mice treated with 5-aminolevulinic acid or methyl 5-aminolevulinate. | 2006 Aug |
|
| Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. | 2006 Feb |
|
| The temperature dependence of porphyrin production in Propionibacterium acnes after incubation with 5-aminolevulinic acid (ALA) and its methyl ester (m-ALA). | 2006 Jan |
|
| Treatment of basal cell carcinoma with topical methylaminolaevulinate photodynamic therapy in an organ-transplant recipient. | 2006 Jan |
|
| Gateways to clinical trials. | 2006 Jan-Feb |
|
| 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. | 2006 Jul-Aug |
|
| Gateways to clinical trials. | 2006 Jun |
|
| Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. | 2006 Jun |
|
| A case of focal dermal hypoplasia (Goltz) syndrome with exophytic granulation tissue treated by curettage and photodynamic therapy. | 2006 Mar |
|
| [Dynamic phototherapy in dermatology: current uses and future perspectives]. | 2006 May |
|
| Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. | 2006 May |
|
| The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid. | 2006 May 1 |
|
| Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study. | 2006 Nov |
|
| Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. | 2006 Oct |
|
| Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. | 2006 Sep |
|
| Topical methyl aminolevulinate photodynamic therapy for the treatment of folliculitis. | 2007 Aug |
|
| Methyl aminolevulinate: actinic keratoses and Bowen's disease. | 2007 Jan |
|
| Photodynamic therapy for actinic keratoses. | 2007 Jan |
|
| Identification of tetrapyrrole compounds excreted by Rhodobacter sphaeroides and sources of the methyl hydrogens of bacteriochlorophyll a biosynthesized by R. sphaeroides, based on 13C-NMR spectral analysis of coproporphyrin III tetramethyl ester. | 2007 Jul |
|
| Photodetection of basal cell carcinoma using methyl 5-aminolaevulinate-induced protoporphyrin IX based on fluorescence image analysis. | 2007 Jul |
|
| Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. | 2007 May |
|
| Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. | 2007 May-Jun |
|
| Photodynamic therapy for cutaneous verrucous carcinoma. | 2007 Sep |
Patents
Sample Use Guides
Using a spatula, apply a layer of METVIXIA Cream (Methyl aminolevulinate) about 1 mm thick to the lesion and the surrounding 5 mm of normal skin. Do not apply more than one gram (half tube) of METVIXIA Cream per treatment session.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:25 GMT 2023
by
admin
on
Fri Dec 15 15:34:25 GMT 2023
|
| Record UNII |
585NM85KYM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000171207
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
WHO-ATC |
L01XD03
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
NCI_THESAURUS |
C1420
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
WHO-VATC |
QL01XD03
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
||
|
NDF-RT |
N0000175846
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
724125
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
585NM85KYM
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
SUB22645
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
585NM85KYM
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
DB00992
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
337068
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
C475457
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
DTXSID3048570
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
157922
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
168
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
m7360
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
METHYL AMINOLEVULINATE
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
100000087993
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
C76305
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY | |||
|
33320-16-0
Created by
admin on Fri Dec 15 15:34:25 GMT 2023 , Edited by admin on Fri Dec 15 15:34:25 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
